Erberto Carluccio
Overview
Explore the profile of Erberto Carluccio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1027
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fortuni F, Bernetti C, Carluccio E
Eur Heart J Cardiovasc Imaging
. 2025 Feb;
PMID: 39918100
No abstract available.
2.
Ciliberti G, Fortuni F, Santucci A, Timi A, Barnoffi E, Coiro S, et al.
Int J Cardiol
. 2025 Feb;
424:133039.
PMID: 39914630
Background: Myocardial infarction without obstructive coronary artery disease (MINOCA) is a challenging condition which requires appropriate management and therapy. Although specific guidelines and recommendations for this condition have been introduced,...
3.
Paolillo S, Basile C, Marzano F, Bruzzese D, Agostoni P, Mattavelli I, et al.
ESC Heart Fail
. 2025 Feb;
PMID: 39909062
Aims: The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF with reduced ejection fraction (HFrEF) a pharmacological approach based on four...
4.
Fortuni F, Biagioli P, Carluccio E
J Am Soc Echocardiogr
. 2025 Jan;
PMID: 39884446
No abstract available.
5.
Palazzuoli A, Pirrotta F, Cartocci A, Delcuratolo E, Dini F, Correale M, et al.
Ther Adv Cardiovasc Dis
. 2024 Nov;
18:17539447241285136.
PMID: 39611607
Background: Sacubitril/valsartan (S/V) is a cornerstone treatment for heart failure (HF). Beneficial effects on hospitalization rates, mortality, and left ventricular remodeling have been observed in patients with heart failure and...
6.
Association of non-cardiac comorbidities and sex with long-term Re-hospitalization for heart failure
Pontiroli A, Tagliabue E, Madotto F, Leoni O, Antonelli B, Carluccio E, et al.
Eur J Intern Med
. 2024 Oct;
131:125-132.
PMID: 39482163
Heart failure (HF) often coexists with non-cardiac comorbidities (NCC), but their association with long-term HF re-hospitalizations is not defined. Using the Lombardy Regional Health Database, that includes >10 million residents,...
7.
Fortuni F, Carluccio E, Ambrosio G
Int J Cardiol
. 2024 Sep;
417:132531.
PMID: 39245074
No abstract available.
8.
Colombo D, Mercurio V, Klersy C, Temporelli P, Rossi A, Carluccio E, et al.
J Cardiovasc Med (Hagerstown)
. 2024 Jul;
25(9):693-699.
PMID: 39083064
Aims: Little research has investigated how sex may affect the prognosis of patients with chronic heart failure (HF). The present study was aimed at exploring sex-specific differences in prognosis in...
9.
Correale M, Pelaggi G, Catanoso M, Micciche S, Teresi L, Bonanno S, et al.
Heart Fail Rev
. 2024 Jul;
29(5):1135-1143.
PMID: 39044114
In recent years, thanks to the advent of new classes of drugs (ARNI and SGLT2-i), the prognosis of patients suffering from heart failure with reduced ejection fraction (HFrEF) has gradually...
10.
Vergaro G, Aimo A, Gentile F, Mandoli G, Focardi M, Castiglione V, et al.
ESC Heart Fail
. 2024 Jul;
11(6):3523-3529.
PMID: 38988051
Aims: Vericiguat is a soluble guanylate cyclase stimulator and improves survival in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and an increased risk of decompensation. As real-world...